RT Journal Article
SR Electronic
T1 Personalized Computational Heart Models with T1-Mapped Fibrotic Remodeling Predict Risk of Sudden Death Risk in Patients with Hypertrophic Cardiomyopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.04.21264520
DO 10.1101/2021.10.04.21264520
A1 O’Hara, Ryan P.
A1 Binka, Edem
A1 Prakosa, Adityo
A1 Zimmerman, Stefan L.
A1 Cartoski, Mark J.
A1 Abraham, M. Roselle
A1 Lu, Dai-Yin
A1 Boyle, Patrick M.
A1 Trayanova, Natalia A.
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.04.21264520.abstract
AB Hypertrophic cardiomyopathy (HCM) causes sudden cardiac death (SCD) due to ventricular arrhythmias (VA) manifesting from myocardial fibrosis proliferation. Current clinical risk stratification criteria inadequately identify at-risk patients in need of primary prevention of VA. Here, we use mechanistic computational modeling of the heart to analyze how HCM-specific remodeling of the heart promotes arrhythmogenesis and to develop a personalized strategy to forecast risk of VAs in these patients. We combine contrast-enhanced cardiac magnetic-resonance (CMR) imaging and T1 mapping data to construct digital replicas of HCM patient hearts that represent the patient-specific distribution of focal and diffuse fibrosis and evaluate the substrate propensity to VA. Our analysis indicates that the presence of diffuse fibrosis, which is rarely assessed in these patients, increases arrhythmogenic propensity. In forecasting future VA events in HCM patients, the imaging-based computational heart approach achieved 84.6%, 76.9%, and 80.1% sensitivity, specificity, and accuracy, respectively, and significantly outperformed current clinical risk predictors. This novel VA risk assessment may have the potential to prevent SCD and help deploy primary prevention appropriately in HCM patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH grants R01HL142496 and R01HL126802 to N.T., a grant from the Leducq Foundation to N.T., an NIH T32 Fellowship (HL125239) to E.B., and a National Science Foundation Graduate Research Fellowship (DGE-1746891) to R.O.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.hopkinsmedicine.org/institutional_review_board/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableSource data is available where possible. Raw numerical data (Figures 2, 4, and 5) has been provided as supplemental material for peer review and will be made available via figshare prior to publication once the manuscript is accepted. Patient imaging and clinical data used in this article will be available for reuse upon reasonable request to the corresponding author and approval from the Institutional Review Board at Johns Hopkins Hospital.